CG Oncology: Promising Data, But Looks Expensive

wildpixel Fresh from its large, $380mn IPO in January, CG Oncology (NASDAQ:CGON) achieved high success after its bladder cancer molecule cretostimogene grenadenorepvec demonstrated a 75.2% complete response at any time in 105 patients. The study was a phase 3 monotherapy study in NMIBC or high-risk non-muscle invasive bladder cancer that's unresponsive to Bacillus Calmette Guerin. This data, presented on May 3, was quickly followed on May 24 by data from a phase 2 study of the same molecule, this time in co ...